Checkpoint Therapeutics (CKPT)
(Delayed Data from NSDQ)
$2.41 USD
-0.02 (-0.82%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $2.41 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth D Momentum D VGM
Income Statements
Fiscal Year end for Checkpoint Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 1 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 1 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 52 | 59 | 57 | 24 | 27 |
Income After Depreciation & Amortization | -52 | -58 | -57 | -23 | -25 |
Non-Operating Income | 0 | -4 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -52 | -63 | -57 | -23 | -25 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -52 | -63 | -57 | -23 | -25 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -52 | -63 | -57 | -23 | -25 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -58 | -57 | -23 | -25 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -52 | -58 | -57 | -23 | -25 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 18.74 | 8.84 | 7.60 | 5.58 | 3.53 |
Diluted EPS Before Non-Recurring Items | -3.17 | -7.09 | -7.50 | -4.10 | -7.00 |
Diluted Net EPS (GAAP) | -3.17 | -7.09 | -7.50 | -4.10 | -7.00 |
Fiscal Year end for Checkpoint Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.04 | 0.00 | 0.01 | 0.03 | 0.03 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.04 | 0.00 | 0.01 | 0.03 | 0.03 |
SG&A, R&D, and Dept/Amort Expenses | 6.71 | 10.95 | 10.18 | 7.74 | 16.23 |
Income After SG&A, R&D, and Dept/Amort Expenses | -6.67 | -10.95 | -10.17 | -7.71 | -16.20 |
Non-Operating Income | 0.00 | 0.00 | -8.96 | 1.98 | -0.33 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -6.67 | -10.95 | -19.13 | -5.72 | -16.52 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -6.67 | -10.95 | -19.13 | -5.72 | -16.52 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -6.67 | -10.95 | -19.13 | -5.72 | -16.52 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 36.53 | 33.93 | 17.31 | 19.99 | 15.70 |
Diluted EPS Before Non-Recurring Items | -0.18 | -0.33 | -1.10 | -0.29 | -1.05 |
Diluted Net EPS (GAAP) | -0.18 | -0.33 | -0.94 | -0.29 | -1.05 |